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SUMMARY 
 
Despite much research, whether mature adipocytes proliferate remains 
controversial. Here, we examined 5-bromo-2′-deoxyuridine 
(BrdU)-labelling of mature adipocytes. Although BrdU incorporation 
into subcutaneous adipocytes was less than that in visceral adipocytes, 
pioglitazone (Pio) treatment increased BrdU incorporation in 
subcutaneous, but not visceral, adipocytes in rats. Fully differentiated 
3T3-L1 adipocytes exhibited an increase in cell number and BrdU 
incorporation with time, with this increase enhanced by Pio treatment. 
We therefore screened for genes that encode growth factors regulated 
by Pio, and selected proliferin (PLF). Both gene silencing of PLF by 
small interfering RNA and treatment with anti-PLF antibody 
suppressed proliferation in 3T3-L1 adipocytes. In adipocytes isolated 
from Pio-treated rats, the tissue-specific pattern of PLF expression was 
similar to that of BrdU incorporation. Administration of an anti-PLF 
antibody to mice reduced BrdU incorporation into adipocytes. Mature 
adipocytes thus have the ability to replicate, and this proliferation is 
positively regulated by PLF.  
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INTRODUCTION 
 
There is growing evidence that adipocytes regulate whole-body energy 
homeostasis and insulin sensitivity. A “Western lifestyle” including a 
high-fat diet and lack of exercise causes excessive fat accumulation in 
adipocytes, which in turn leads to obesity, a major risk factor for type 2 
diabetes, hypertension, dyslipidemia and atherosclerosis. Underlying 
insulin resistance plays a pivotal role in the pathogenesis of these disorders; 
however, the mechanisms that link obesity and impaired insulin signaling 
are not fully understood. Obesity is associated with a low-grade 
inflammation characterized by macrophage infiltration into adipose tissue1, 
2. Monocyte chemoattractant protein-1 (MCP-1), which recruits monocytes, 
leukocytes and other inflammatory cells, plays a crucial role in this 
process3. Insulin resistance and hepatic steatosis induced by a high-fat diet 
are reduced in MCP-1 KO mice4. It has been proposed that the capacity of 
adipose tissue to expand, rather than the absolute amount of adipose tissue, 
is critical for metabolic homeostasis. When this capacity is exceeded, lipid 
accumulates in skeletal muscle and liver, which, in turn, attenuates insulin 
action5. Therefore, understanding the mechanism by which new adipocytes 
are generated is important. The finding that approximately 10% of fat cells 
are renewed annually at all adult ages and levels of body mass index 
indicates that the ability to provide newborn adipocytes is limited6. It is 
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generally considered that the mature adipocyte is unable to proliferate7 and 
that it is generated from a mesenchymal stem cell in the adipose tissue8. In 
the first phase, this multipotent stem cell turns into a preadipocyte, which 
cannot be distinguished morphologically from the precursor stem cells. In 
the second phase, terminal differentiation, the preadipocyte acquires the 
characteristics of the mature adipocyte, including lipid droplets, insulin 
sensitivity, and the ability to secrete adipokines. Terminal differentiation 
consists of a cascade of transcriptional events. The transient induction of 
the CCAAT-enhancer binding proteins C/EBPβ and C/EBPδ leads directly, 
or in concert with Krüppel-like factor 5 (KLF5), to the induction of 
peroxisome proliferator-activated receptor γ (PPARγ) and C/EBPα, the 
central transcriptional regulator of adipocytes. They play a major role in the 
individual or synergistic induction of adipocyte-specific genes, including 
those encoding adipocyte fatty acid-binding protein (aP2), lipoprotein 
lipase (LPL), adiponectin and glucose transporter type 4 (Glut4).  
Adipose tissue is classified into visceral and subcutaneous adipose 
tissue according to its anatomical location in the body. Multiple lines of 
evidence indicate that an increase in visceral adipose tissue is associated 
with insulin resistance, hyperlipidemia, type 2 diabetes and atherosclerosis9, 
10, whereas the finding that transplantation of subcutaneous adipose tissue 
improves insulin sensitivity11 indicates a beneficial role for subcutaneous 
adipose tissue. Treatment with thiazolidinedione, which specifically targets 
PPARγ, increases subcutaneous adipose tissue and decreases visceral 
adipose tissue12, a process associated with improved insulin sensitivity. 
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Thiazolidinedione treatment also decreases the cell size of adipocytes, with 
a concomitant increase in the number of cells13. These findings show that 
thiazolidinedione accelerates adipocyte hyperplasia, especially in 
subcutaneous adipose tissue; however, as its target, PPARγ, first appears 
during terminal differentiation, it is difficult to understand how this agent 
could have an effect on preadipocyte or mesenchymal stem cells. 
Accordingly, two possibilities arise: the first is that thiazolidinedione might 
stimulate mature adipocytes to secrete substances that promote the 
proliferation of precursor cells; the second is that thiazolidinedione might 
directly induce the proliferation of mature adipocytes.  
In this study, we investigated the mechanism by which pioglitazone 
(Pio), a member of the thiazolidinedione class of drugs, increases the 
number of adipocytes. First, we ascertained that mature adipocytes 
incorporate 5-bromo-2′-deoxyuridine (BrdU), a thymidine analog, which 
indicates that the mature adipocytes undergo DNA synthesis. Second, we 
found that Pio accelerated mature adipocyte proliferation in vivo and in 
vitro. We then screened for genes encoding proteins that could mediate the 
proliferative signals of PPARγ, and noted that a previous microarray study 
showed that proliferin (PLF) is upregulated by Pio, rosiglitazone and 
troglitazone14. We confirmed that Pio elevated the mRNA and protein level 
of PLF in 3T3-L1 adipocytes, and that this was associated with increased 
cell proliferation. Since PLF acts via a paracrine mechanism15, we found 
that treatment with an anti-PLF antibody resulted in reduced adipocyte 
proliferation in vivo and in vitro. 
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Taken together, our results indicate that PLF regulates adipocyte 
proliferation. 
 
 
RESULTS 
 
Effect of Pio on cell proliferation in adipose tissue 
To evaluate cell proliferation, we used immunohistochemistry to measure 
BrdU incorporation into adipose tissue and non-adipose tissue (i.e., 
intestine). Because cell proliferation in adipose tissue is much less active 
than that in intestine (Fig. 1a), repeated intraperitoneal injections of BrdU 
were required. A single BrdU injection labels cells for 5–6 h16, and so we 
expected that cells in S-phase would be detected for approximately 12–18 h 
by our method. Because the animals were sacrificed 24 h after the first 
injection, the possibility that labeled cells might transform from 
preadipocytes into mature adipocytes was excluded. In the epididymus, 
BrdU-labeled cells were detected in the perivascular area, which consists of 
the stromal vascular fraction (SVF; Fig. 1b). Furthermore, BrdU-labeled 
cells with the characteristics of mature adipocytes were observed (Fig. 1c). 
Double-color immunostaining for BrdU and the mature adipocyte-specific 
protein adiponectin confirmed that adiponectin was present in the 
cytoplasm of the BrdU-labeled cells (Fig. 1d). Taken together, these results 
suggest that mature adipocytes have the ability to proliferate. Furthermore, 
BrdU-labeled mature adipocytes in contiguous sections were concomitantly 
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stained with anti-proliferating cell nuclear antigen (PCNA) antibody (Fig. 
1e,f), another marker of proliferating cells17. No apoptotic cells labeled 
with terminal deoxynucleotidyl transferase-mediated biotinylated dUTP 
nick end labeling (TUNEL) were detected in the BrdU-positive mature 
adipocytes (Supplementary Fig. 1).  
To confirm that mature adipocytes incorporate BrdU, the mature 
adipocytes were separated from the SVF by collagenase digestion, DNA 
was extracted, and BrdU incorporation was quantified. No significant 
difference was observed in BrdU incorporation between mature adipocytes 
and SVF cells (Fig. 2a). Therefore, we can exclude the possibility that the 
apparent BrdU incorporation in mature adipocytes was due to 
contamination with SVF cells. Visceral adipose tissues (i.e, epididymal, 
mesenteric and perirenal adipose tissues) were more active in incorporating 
BrdU than subcutaneous adipose tissue (epididymal vs subcutaneous; p= 
0.032, mesenteric vs subcutaneous; p=0.044). Treatment with Pio for 14 d 
significantly (0.005% Pio vs control; P=0.048, 0.025% Pio vs control; 
P=0.026) increased BrdU incorporation in subcutaneous adipocytes, but not 
in visceral adipocytes, (Fig. 2b). These results suggest that, in mature 
subcutaneous adipocytes, activation of PPARγ by its agonist Pio  leads to 
an increase in the rate of proliferation. The pattern of PCNA protein 
expression levels in isolated mature adipocytes from subcutaneous and 
visceral fat (Fig. 2c) was similar to that of BrdU incorporation (Fig. 2a,b). 
Moreover, the protein expression of PCNA was increased by Pio treatment 
in subcutaneous adipocytes (Fig. 2c), supporting the results for BrdU 
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incorporation. Although quantitative estimation was difficult, treatment 
with Pio did not increase the number of preadipocyte factor-1 
(Pref-1)-labeled cells in adipose tissue including subcutaneous fat 
(Supplementary Fig. 2). Because Pref-1 is a marker of preadipocytes, this 
result implies that the Pio treatment did not influence preadipocyte 
proliferation. 
 
Effect of Pio and 15-deoxy-Δ12,14-prostaglandin J2 on cell 
proliferation in cultured adipocytes 
Fully differentiated 3T3-L1 adipocytes were re-seeded into 6-well plates to 
determine if they are capable of proliferation. Although adipocyte 
proliferation was less active at 10 d than at 5 d after differentiation, the cell 
number increased markedly between 0 h, 24 h and 48 h after the cell 
attachment to the plate (Fig. 3a). Both Pio and 
15-deoxy-Δ12,14-prostaglandin2 (PGJ2) enhanced the proliferation rate 
(control vs Pio; P=0.002, control vs PGJ2; P=0.027: Fig. 3b). Adiponectin 
was detected in more than 90% of re-seeded adipocytes, whereas Pref-1 
was not detected in these cells (Supplementary Fig. 3). Hence, we can rule 
out the possibility that the increases in cell number were due to 
contamination by preadipocytes. Furthermore, lipid droplets, a 
characteristic of mature adipocytes, were detected in more than 90% of the 
cells examined (Fig. 4a). Supporting the results in Fig. 3b, BrdU 
incorporation in the 3T3-L1 adipocytes was increased by treatment with 
Pio or PGJ2 (control vs Pio; P=0.0494, control vs PGJ2; P=0.017: Fig. 
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3c,d). Together, these results suggest that activation of PPARγ in fully 
differentiated 3T3-L1 adipocytes leads to cell proliferation. To further 
confirm whether these mature adipocytes are capable of proliferating, we 
performed cell cycle analyses using flow cytometry. Cells in G0/G1, S and 
G2/M phase were observed amongst the fully differentiated 3T3-L1 
adipocytes (Fig. 3g). In addition, we examined cell proliferation in primary 
cultures of subcutaneous and mesenteric adipocytes. Since passage of 
primary cultured mature adipocytes is difficult, differentiation was induced 
at 70% confluence. The efficiency of differentiation in the primary cultured 
adipocytes was inferior to that of 3T3-L1 adipocytes; however, we were 
able to discriminate the differentiated cells by staining for adiponectin. We 
therefore carried out double staining for adiponectin and BrdU. More than 
80% of the subcutaneous and mesenteric cells stained positive for 
adiponectin (Fig. 3e). The proportion of BrdU-labeled cells within the 
adiponectin-positive cell population was significantly smaller in 
subcutaneous adipocytes than in mesenteric adipocytes; however, treatment 
with 10 μM Pio significantly increased the proportion of BrdU-labeled 
cells within the adiponectin-positive cells (subcutaneous vs mesenterin; 
P=0.018, control vs Pio 10 μM in subcutaneous; P=0.036: Fig. 3f).  
Incubation of fully differentiated 3T3-L1 adipocytes with 10 μM 
aphidicolin, an inhibitor of DNA polymerase α, δ and ε, for 48 h resulted in 
marked lipid droplet formation (Fig. 4a). Although treatment with Pio 
significantly decreased the PPARγ mRNA level, it significantly increased 
adiponectin and fatty acid synthase (FAS) mRNA levels (Fig. 4b–e). 
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Treatment with Pio significantly decreased the MCP-1 mRNA level (Fig. 
4h). Our result supports the previous finding that Pio downregulates PPARγ 
mRNA expression in mature, but not partially differentiated adipocytes18. 
Treatment with aphidicolin significantly suppressed expression of PPARγ 
mRNA and its downstream genes, including the genes encoding aP2, LPL 
and adiponectin (Fig. 4b–d,f), and elevated the mRNA expression of genes 
encoding cytokines such as MCP-1 and interleukin-6 (IL-6; Fig. 4h,i). 
These results indicate that DNA polymerase influenced the morphology 
and gene expression of mature adipocytes and support our contention that 
these cells proliferate. 
 
Role of PLF on adipocyte proliferation 
Next, we explored the factors regulating mature adipocyte proliferation. 
Since we observed that proliferation was accelerated by Pio, we screened 
for genes regulated by the thiazolidinedione class of drugs. In published 
microarray data from 3T3-L1 adipocytes14, we noted that the growth factor 
PLF was significantly upregulated by three thiazolidinediones (i.e., Pio, 
rosiglitazone and troglitazone). PLF, also termed mitogen-regulated protein 
(MRP), is a member of the prolactin/growth hormone family, and is 
involved in the angiogenesis of placenta19, 20. PLF, secreted as a paracrine 
agent, binds to the insulin-like growth factor II (IGF-II)/ 
cation-independent mannose 6-phosphate (M6P) receptor, the signal of 
which can be mediated with Gi protein21, 22. Here, we detected PLF mRNA 
at day 2 after the initiation of differentiation of 3T3-L1 adipocytes; the 
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mRNA level then remained stable at days 5 and 9 (Supplementary Fig. 4). 
Four PLF/MRP genes, Plf1, Plf2, Mrp3 and Mrp4, have been cloned and 
shown to share 91% amino acid sequence identity15. To determine which 
subclass is expressed in 3T3-L1 adipocytes, PCR of PLF cDNA was 
performed as previously described15. Direct sequence analysis revealed that 
the PCR product completely coincided with PLF1 (Supplementary Fig. 5). 
Incubation with Pio increased PLF mRNA as well as protein levels in cell 
lysates and culture media (Fig. 5a,b). Gene silencing of PLF by siRNA 
significantly decreased both the cell number and BrdU incorporation in the 
fully differentiated adipocytes (P=0.001, P=0.007: Fig. 5c,d). Addition of 
goat anti-PLF antibody to the non transfected adipocyte culture medium 
significantly suppressed cell proliferation, when compared with the effect 
of addition of goat IgG (P=0.001, P=0.001: Fig. 5c,d). Incubation with 
IGF-II significantly increased cell proliferation, whereas pertussis toxin 
(PTx) treatment significantly decreased cell proliferation (control vs 
IGF2;P=0.001, P=0.014, control vs PTx;P=0.001, P=0.011: Fig. 5e,f). Both 
gene silencing and antibody treatment reduced the mRNA expression levels 
of PPARγ, LPL and adiponectin, but not MCP-1 in the 3T3-L1 adipocytes 
(Supplementary Fig. 6b,e). 
We then examined the expression of the PLF protein in rat 
adipocytes. PLF was expressed abundantly in white adipose tissue and 
brown adipose tissue, whereas low PLF levels were detected in pancreas, 
liver and skeletal muscle (Supplementary Fig. 7). Interestingly, PLF protein 
expression in epididymal and mesenteric fat was significantly higher than 
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that in subcutaneous fat, and treatment with Pio significantly increased PLF 
expression in subcutaneous fat only (control vs Pio; P=0.001: Fig. 6a,b). 
These results were similar to the results for BrdU incorporation shown in 
Fig. 2b., supporting our speculation that PLF regulates mature adipocyte 
proliferation in vivo. To confirm this, we studied the effect of an anti-PLF 
antibody in vivo. Administration of the anti-PLF antibody to mice resulted 
in a decrease of BrdU incorporation in adiponectin-positive epididymal 
adipocytes (P=0.006: Fig. 6c).  
 
 
DISCUSSION 
 
Numerous researchers have clarified the origin of adipocyte progenitor 
cells and the mechanism(s) by which they differentiate into adipocytes, but 
there has been little debate regarding the possibility of mature adipocyte 
proliferation. A recent study concluded that adipocyte number increases in 
the early stage in man6. The authors claimed that adipocytes do not divide 
or express mitotic markers, although no evidence is cited. The notion that 
mature adipocytes are unable to replicate is poorly described in recent 
reviews23, 24. Rodeheffer et al. 25, who identified the undifferentiated 
adipocyte precursor subpopulation within adipose tissue stroma, stated the 
inability of mature adipocytes to replicate on the basis of a microscopic 
morphological study carried out by Simon26 in 1965. During the period 
from 1970 through 1990, the possibility of mature adipocyte proliferation 
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was a matter of debate. Several in vivo studies were performed using 
labeled thymidine27, 28 Sugihara et al.29 provided evidence that “ceiling” 
cultures of mature white adipocytes exhibit morphologically dividing cells. 
Although there has been no conclusive evidence to support the assertation, 
terminally differentiated and lipid-filled adipocytes have been generally 
considered, since the 1990’s, to be incapable of division. This is despite 
recent research demonstrating mature adipocyte proliferation by 
BrdU-labeling30 or microscopic observation of organotypic culture 
system31.  
Here, we assessed mature adipocyte proliferation by measuring 
BrdU incorporation in adipose tissue. Our detection of BrdU-labeled 
mature adipocytes was consistent with the detection of BrdU-labeled white 
mature adipocytes after sympathetic denervation reported by Foster et al.30. 
We confirmed that the labeled cells were actually mature adipocytes by 
using double-color immunostaining for BrdU and adiponectin, a marker of 
mature adipocytes. Our finding that a proportion of BrdU-positive mature 
adipocytes were also positive for PCNA, a different marker of proliferation, 
further supports our contention of mature adipocyte proliferation. BrdU can 
integrate into apoptotic cells as a result of DNA damage and repair32, and 
thiazolidinediones can induce apoptosis in adipocytes33. Therefore, BrdU 
incorporation in mature adipocytes, particularly those treated with 
thiazolidinediones, should be interpreted carefully. Other evidence suggests 
that the use of BrdU labeling criteria makes it highly unlikely that apoptotic 
cells would be mistaken for newborn cells in vivo34. Indeed, in our study, 
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no adipocytes that simultaneously stained for BrdU and TUNEL were 
detected, even in visceral adipose tissue. Since the animals were sacrificed 
24 h after the first BrdU injection, the possibility that BrdU-labeled 
preadipocytes turned into mature adipocytes can be ruled out. Therefore, 
our results demonstrate that DNA synthesis, the early phase of cell division, 
occurs in mature adipocytes in vivo.  
To quantify BrdU incorporation, adipocytes were separated from 
SVF by collagenase digestion. Surprisingly, BrdU incorporation in 
adipocytes was not inferior to that in SVF. Our experiments demonstrated 
that BrdU incorporation was higher in visceral than in subcutaneous 
adipocytes. Treatment with Pio increased BrdU incorporation in 
subcutaneous adipocytes in a dose-response manner, whereas visceral 
adipocytes did not respond to Pio. We suggest that a Pio-induced increase 
in the proliferation of subcutaneous adipocytes may be the mechanism 
behind the Pio-induced increase in subcutaneous fat mass in type 2 diabetes 
patients reported by Miyazaki et al.12. Conversely, treatment with Pio did 
not increase preadipocyte number. Hence, the effect of Pio on cell number 
cannot be explained by recruitment of progenitor cells. 
To examine whether cultured mature adipocytes proliferate, we 
re-seeded fully differentiated 3T3-L1 adipocytes onto plates to remove 
contact inhibition. Both the number of adipocytes and the level of BrdU 
incorporation increased with time in culture. Furthermore, cells that had 
entered the cell cycle were detected by flow cytometry. Although the 
possibility that undifferentiated preadipocytes contributed to these results 
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cannot be excluded completely, our observations that more than 90% of 
cells stained with an anti-adiponectin antibody, but not anti-Pref-1 antibody, 
and that lipid droplets were present in these cells, imply that the vast 
majority of the cells examined were differentiated adipocytes. Our result 
that subcutaneous adipocytes have a lower proliferative activity than 
visceral adipoctyes, but only subcutaneous adipocytes respond to Pio, was 
confirmed in primary culture. Although we are unable to explain this 
difference between the behavior of these two cell types, it may be related to 
their distinct expression profiles of multiple genes involved in embryonic 
development and pattern specification, which are intrinsic and persist 
during in vitro culture and differentiation35.  
Our result that the PPARγ agonist Pio and the PPARγ ligand PGJ2 
both accelerated 3T3-L1 adipocyte replication strongly suggests that 
activation of PPARγ promotes mature adipocytes proliferation. We 
therefore screened the published literature for growth factors regulated by 
PPARγ. Among numerous studies, most of which showed that 
thiazolidinediones inhibit cell proliferation in various cell types, including 
cancer cells36, a microarray study performed by Sears et al.14 indicated that 
thiazolidinediones upregulate PLF in 3T3-L1 adipocytes. PLF was 
identified by Linzer et al. in 1984 as a member of the prolactin/growth 
hormone family in mouse 3T3 cells19. Four PLF/MRP genes, Plf1, Plf2, 
Mrp3 and Mrp4, have been cloned in the mouse and shown to share 91% 
amino acid sequence identity15. PLF genes are expressed markedly in 
uteroplacental tissue and are thus thought to be involved in angiogenesis of 
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the uterus and placenta37. Mrp3 is induced in wound-edge keratinocytes 
during cutaneous wound healing, whereas Mrp3 and Mrp4 are found in the 
hair follicles38. PLFs are speculated to be involved in the growth of 
neuroblastoma cells39 and hematopoietic stem cells40. Here, we showed that, 
among various organs in adult rats, PLF protein was most abundantly 
expressed in white adipose tissue. We found that Pio increased not only the 
expression level of PLF mRNA, but also the level of protein secreted into 
the medium in 3T3-L1 adipocytes. Accordingly, we postulated that PLF 
might regulate adipocyte proliferation. Our finding that 3T3-L1 adipocyte 
proliferation is inhibited when PLF action is attenuated by either anti-PLF 
antibody or PLF siRNA strongly supports this. The observation that 
inhibition of PLF action led to a decrease in the mRNA expression of 
PPARγ and its downstream genes, LPL and adiponectin, in a similar 
manner to treatment with the DNA polymerase inhibitor aphidicolin 
suggests that cell proliferation might influence adipocyte functions to 
regulate glucose and lipid metabolism. Since PLF action is mediated via 
the IGF-II/cation-independent M6P receptor, which is PTx sensitive 22, 
we evaluated the effects of IGF-II and PTx on cell proliferation in 3T3-L1 
adipocytes. As expected, PTx abolished cell replication, whereas IGF-II 
stimulated cell replication. These results support the notion that PLF acts 
on the IGF-II/cation-independent M6P receptor in adipocytes; however, 
further study is necessary. Interestingly, Connor et al. 41 reported that PLF 
mRNA levels are increased by estradiol and reduced by dexamethasone in 
the BNL cell line. We observed that treatment with dexamethasone reduced 
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proliferation and PLF mRNA levels in 3T3-L1 adipocytes (data not shown). 
Considering the effect that glucocorticoids and estrogen have on the 
distribution of adipose tissue and insulin sensitivity, further research into 
the role of PLF in adipocyte proliferation can be expected to provide new 
insight in diabetic research. In addition, we found that the tissue-specific 
pattern of PLF protein expression was similar to that of BrdU incorporation 
in adipocytes isolated from subcutaneous adipose and various visceral 
adipose tissues following treatment with Pio. These results imply that PLF 
regulates the proliferation of mature adipocytes in vivo, and that the 
difference between subcutaneous and visceral adipocyte proliferation might 
be explained by their ability to secrete PLF. Moreover, our results 
indicating that treatment with anti-PLF antibody significantly decreased 
BrdU incorporation and elimination of PLF throughout the body resulted in 
a decrease of mature adipocytes proliferation.  
In conclusion, our results strongly suggested that mature adipocytes 
have the ability to proliferate in adipose tissue, as well as in cultured 
adipocytes. PLF may contribute to the proliferation of these mature 
adipocytes. 
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FIGURE LEGENDS 
 
Fig. 1. Immunohistochemical staining of BrdU in the adipose tissue.  
Male Wistar rats were intraperitoneally injected with 200 mg/kg of BrdU 
three times 24 h before sacrifice. The small intestinal tract (control) (a) and 
epididymal adipose tissue (b–f) were harvested, processed for paraffin 
sections, and immunohistochemically stained as described in the Methods. 
(a) Tissue from the small intestinal tract contained abundant BrdU-labeled 
cells. (b) BrdU-labeled cells were observed in the stromal vascular area in 
epididymal adipose tissue. (c) BrdU-labeled nuclei were detected in cells 
with the appearance of mature adipocytes. (d) Double-color 
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immunohistochemical staining for BrdU and adiponectin. BrdU-positive 
nuclei (3,3'-Diaminobenzidine, DAB: brown) were detected (black arrow) 
in adiponectin-positive cytosols (tetramethylbenzidine, TMB: blue). (e, f) 
Immunohistochemical staining for BrdU (e) and PCNA (f) in contiguous 
sections. The same nucleus was stained simultaneously.  
 
Fig. 2. Analysis of BrdU incorporation in adipocytes and SVF isolated 
from subcutaneous and visceral adipose tissues, and the effect of Pio 
treatment  
(a) To quantitatively evaluate BrdU incorporation, the adipocytes and SVF 
in each adipose tissue isolated from male Wistar rats were separated by 
collagenase digestion. DNA extracted from adipocytes and SVF cells was 
spotted onto a nitrocellulose membrane, and BrdU incorporation and total 
DNA levels were visualized with an anti-BrdU antibody (top panel) and 
anti-DNA antibody (middle panel), respectively. A histogram of BrdU 
incorporation into adipocytes (white bar) and SVF (black bars) in visceral 
adipose tissues relative to that in subcutaneous adipose tissue (100%) is 
shown; n = 5; *, P<0.05 vs subcutaneous adipose tissue (bottom panel). 
Sub, subcutaneous; Epi, epididymal; Mes, mesenteric; Ren, perirenal. (b) 
BrdU incorporation in adipocytes isolated from male Wistar rats housed 
with food containing various amounts of Pio. The top panel shows a typical 
result for the effect of food containing 0.005% Pio on BrdU incorporation 
into adipocytes. The bottom panel shows the effect of food containing 0% 
Pio (Control, white bar), 0.005% Pio (black bar) and 0.025% Pio (grey bar) 
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on BrdU incorporation in various visceral adipose tissues; all values are 
relative to the level of BrdU incorporation in the subcutaneous adipocyte 
isolated from the control (100%). n = 6; **, P < 0.01 vs control. (c) 
Expression of PCNA protein in subcutaneous, epididymal and mesenteric 
adipocytes isolated from untreated rats (Control) and rats housed with food 
containing 0.005% Pio. The typical results of Western blot in four separate 
experiments were shown. Each adipocyte sample was subjected to 
electrophoresis in a separate gel; however, the electrophoresis, transblot, 
incubation with antibody and enhanced chemiluminescence of the various 
samples were performed simultaneously.  
 
Fig. 3. Cell proliferation in 3T3-L1 adipocytes and the effect of PPARγ 
agonists 
(a) To evaluate cell proliferation, the 3T3-L1 adipocytes were induced to 
fully differentiate, and then 5 d (■) or 10 d (○) later, the cells were 
suspended by trypsin-EDTA treatment and re-seeded into 6-well plates at a 
density of 3 × 103 cells/cm2. The medium was exchanged 24 h later, when 
the cells had attached to the plate, and the cell number was counted 
immediately (0 h), and 24 h and 48 h later. (b) The effect of Pio and PGJ2 
on adipocyte number was examined. After the re-seeded 3T3-L1 adipocytes 
attached to the plate (0 h), the medium was exchanged and the cells were 
incubated for 24 h without treatment (Control, ■), or with 10 μM Pio (●) or 
10 μM PGJ2 (▲). The cell number was counted at 0 h and 24 h. n = 6, *, P 
< 0.05 vs control. (c, d) To assess BrdU incorporation, 3T3-L1 adipocytes 
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were re-seeded into chamber slides at a density of 103 cells/cm2. After the 
cells attached, they were incubated for 24 h without treatment (Control), or 
with 10 μM Pio or 10 μM PGJ2 (J2); the cells were treated with 10 μM 
BrdU for the last 4 h of this incubation period. Immunostaining for BrdU 
was performed, and the cells were counted. Representative images of the 
immunostaining (c) and histograms showing the proportion (%) of 
BrdU-labeled cells in each sample (d) are shown. Data are presented as 
the mean ± s.e.m of 6 independent experiments. *, P < 0.05 vs control. (e, 
f) Primary cultures of preadipocytes derived from subcutaneous and 
mesenteric adipose tissue were cultured in chamber slides. When the cells 
reached 70% confluence, differentiation was initiated. Five d after the 
differentiation, the cells were incubated for a further 24 h with or without 
various concentrations of Pio. Double-color immunostaining for BrdU 
(brown) and adiponectin (red) was performed. Typical results for 
subcutaneous and mesenteric adipocytes (e) and histograms showing the 
proportion (%) of BrdU-positive cells in sets of 5000 adiponectin-positive 
cells derived from subcutaneous adipocytes (black bars) or mesenteric 
adipocytes (white bars) (f) are shown. Data are presented as the mean ± 
s.e.m of 3 independent experiments. *, P < 0.05 vs subcutaneous control. 
(G) The cell cycle in fully differentiated 3T3-L1 adipocytes was analyzed 
by flow cytometry. A typical result from 5 independent experiments is 
shown.  
 
Fig. 4. Effects of Pio and aphidicolin on cell morphology and gene 
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expression 
(a) Differentiated 3T3-L1 adipocytes were suspended by trypsin-EDTA 
treatment, and re-seeded at 5 × 103 cells/cm2 in chamber slides. After 
treatment with 10 μM Pio or 10 μM aphidicolin for 48 h, Papanicolau 
staining (upper panel) and Oil Red O staining (lower panel) was performed. 
(b–i) Passaged differentiated 3T3-L1 adipocytes were incubated without 
treatment (Control), or with 10 μM Pio, 10 μM aphidicolin or 10 μM Pio 
plus 10 μM aphidicolin for 48 h. Total RNA was extracted, and the mRNA 
levels of PPARγ (b), aP2 (c), adiponectin (d), FAS (e), LPL (f), Glut4 (g), 
MCP-1 (h) and IL-6 (i) were measured by real-time PCR, as described in 
Methods. Aphi, aphidicolin. n = 6, *, P < 0.05 vs control. **, P < 0.01 vs 
control. 
 
Fig. 5. Expression of PLF in 3T3-L1 adipocytes 
(a, b) Fully differentiated 3T3-L1 adipocytes, 7 d after induction of 
differentiation, were incubated without treatment (Control) or with 10 μM 
Pio for 24 h, and total RNA, cell lysate and medium were harvested for 
real-time PCR and Western blots. Treatment with Pio increased not only the 
PLF mRNA level (a), but also the PLF protein level in cell lysates and 
media (b). The values in panel (a) are the mean ± s.e.m. of 4 separate 
experiments. **, P < 0.01 vs control. Panel (b) represents a typical result of 
4 independent experiments. (c,d) To assess the effect of PLF knockdown on 
adipocyte proliferation, PLF siRNA was transfected into fully differentiated 
3T3-L1 adipocytes. One day later, cells were suspended by trypsin-EDTA 
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treatment. Cells were re-seeded at a density of 3 × 103 cells/cm2 in 6-well 
plates and the cells were counted (c), as described in Methods. The effect 
of treatment with goat anti-PLF antibody, or goat IgG, was concomitantly 
evaluated. ●, Control; ○, Goat IgG; ■, PLF siRNA; ▲, anti-PLF antibody. 
Cells were also re-seeded in chamber slides at a density of 103 cells/cm2 
and incubated with or without antibodies, as described above, and BrdU 
incorporation was measured (d). n = 5; **, P < 0.01 vs control, ##, P < 0.01 
vs Goat IgG. (e, f) In addition, the effects of treatment with IGF-II and PTx 
were studied to assess the involvement of IGF-II/ cation-independent 
mannose 6-phosphate receptor. The effects of IGF-II and PTx on adipocyte 
number (e) and BrdU incorporation (f) are shown. ●, Control; ■, IGF-II; ▲, 
PTx. n = 5; *, P < 0.05 vs control.  
 
Fig. 6. Expression levels of PLF protein in vivo, and effect of anti-PLF 
antibody on in vivo BrdU incorporation in adipocytes. 
(a, b) Expression of PLF in adipocytes isolated from subcutaneous (Sub), 
epididymal (Epi), mesenteric (Mes) and perirenal (Ren) adipose tissue by 
collagenase digestion, in male Wistar rats housed with food containing 0% 
Pio (Control, white bar), 0.005% Pio (black bar) or 0.025 Pio (grey bar). 
PLF protein levels were assayed by Western blot (a) and quantified (b). 
Data are presented as the mean ± s.e.m of 5 independent experiments. *, P 
< 0.05 vs control. (c) C57BL-CR mice were intraperitoneally injected with 
4 mg/kg goat anti-PLF antibody or goat IgG, and BrdU was administered 
24 h later. BrdU-labeled adipocytes in epididymal adipose tissue were 
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detected with double-color immunohistochemical staining for BrdU and 
adiponectin. The values given are the proportion (%) of BrdU-labeled cells 
in the adiponectin-positive cells, expressed as the mean ± s.e.m. of 6 
independent experiments. **, P < 0.01.  
 
 
 
METHODS 
 
Effect of Pio on cell proliferation in adipose tissue 
Male Wistar rats weighing 250 g were treated with food containing either 
0%, 0.005% or 0.025% Pio for 14 d. Then 200 mg/kg BrdU was 
intraperitoneally administered 3 times over a period of 12 h (i.e., every 4 h). 
The rats were then sacrificed 12 h later, and subcutaneous, epididymal, 
mesenteric and perirenal fats were harvested. Animal care and experimental 
procedures were performed under the approval of the Animal Care 
Committees of Gifu University School of Medicine. 
 
Immunohistochemical staining 
BrdU antibody staining of paraffin sections of the fat tissues was carried 
out using a BrdU In-Situ Detection Kit (Becton Dickinson, Franklin Lakes, 
NJ, USA). As a positive control, tissue from the small intestinal tract of the 
same animal was also harvested and immediately stained, as described 
above. Other immunostaining was preformed using aint-adiponectin 
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antibody (R & D System, Minneapolis, MN, USA), anti-PCNA antibody 
(Santa Cruz, Santa Cruz, CA, USA), anti-Pref-1 antibody (Santa Cruz) and 
Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA).  
 
Dot blot analysis 
To confirm the hypothesis that mature adipocytes incorporate BrdU in vivo, 
isolated mature adipocytes and SVF were obtained by collagenase 
digestion of each adipose tissue. DNA extracted from adipocytes and SVF 
was spotted on a nitrocellulose membrane. Incorporated BrdU was 
visualized with an anti-BrdU antibody (Santa Cruz Biotechnology). The 
detailed method is described in the Supplementary Methods.  
 
Measurement of cell number and BrdU uptake in 3T3-L1 adipocytes 
and primary cultured adipocytes 
3T3-L1 fibroblasts were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 
and 0.1 mg/mL streptomycin, and differentiation induced with 3T3-L1 
differentiation medium (DS Pharma Biomedical, Osaka, Japan). Fully 
differentiated 3T3-L1 adipocytes were suspended by trypsin-EDTA 
treatment and then seeded at a density of 3 × 103/cm2 in 6-well dishes. 
Subsequently, cells were incubated without treatment (control), or with 10 
μM Pio (Takeda, Osaka, Japan), 10 μM aphidicolin, or 10 μM PGJ2 in 
DMEM for 24 h. The cells were suspended again and counted using a 
hemocytometer. To measure BrdU uptake in vitro, isolated adipocytes were 
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seeded in chamber slides and incubated. Ten μM BrdU was added for a 
period of 4 h. The detailed method for assessment of the proliferation of 
primary cultured adipocytes is described in the Supplementary Methods.  
 
Flow cytometry 
Fully differentiated 3T3-L1 adipocytes were suspended by trypsin-EDTA 
treatment, and cell populations in the G0/G1, S and G2/M phases were 
separated using a FACScan flow cytometer (Becton Dickinson 
Immunocytometry System, Becton Dickinson, San Diego, CA, USA). The 
data were analyzed using Cell Quest software (Becton Dickinson). In each 
sample, 10 000 fluorescent cells were counted. 
 
Real-time PCR analysis 
To determine the mRNA expression levels of PPARγ, aP2, LPL, fatty acid 
synthase (FAS), adiponectin and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), real-time PCR analysis was performed using a 
Thermal Cycler Dice (TAKARA, Ohtsu, Japan). Expression levels, 
calculated as copy numbers in each sample, were normalized to the 
expression level of GAPDH. The primer sequences are described in the 
Supplementary Methods.  
 
Antibody administration in vivo 
C57BL-CR mice were injected intraperitoneally with either 4 mg/kg goat 
anti-PLF antibody (Santa Cruz) or goat IgG, in parallel, and then 
 27
administered with BrdU 24 h later, as described above. BrdU-labeled 
adipocytes were detected with double-color immunostaining using an 
anti-BrdU antibody and anti-adiponectin antibody. 
 
Statistics 
Statistical comparisons were performed with Student’s t-test (Figs. 5a and 
6c) and two-factor ANOVA (Fig. 5c and 5d). Other data were analyzed with 
one-factor ANOVA (Dunnett test). All statistical tests were two-tailed. Data 
are given as mean ± s.e.m.. Values of P < 0.05 were considered statistically 
significant. 
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Dot blot analysis 
Isolated mature adipocytes and SVF were obtained by collagenase (type 1, 
Sigma-Aldrich, St. Louis, MO, USA) digestion of each adipose tissue 
dissociated from male Wistar rats. DNA was extracted with proteinase K 
from each cell. Equal amounts of DNA were spotted onto a nitrocellulose 
membrane (Protran ○R  BA85, Whatman, London, UK) using an S&S 
Minifold○R Slot Blot System (Whatman). The membrane was dried at 80°C 
for 2 h, and then heated to 95°C for 10 min in sodium citrate buffer (pH 
6.0). After blocking non-specific binding with 7% (w/v) nonfat dry milk for 
2 h, the membrane was incubated with an anti-BrdU antibody (Santa Cruz) 
in parallel with an anti–single stranded DNA antibody (Millipore, Billerica, 
MA, USA) overnight, followed by incubation with horseradish peroxidase 
(HRP)-conjugated secondary antibody (Santa Cruz). The reaction was 
visualized by means of the ECL system (GE Healthcare, Buckinghamshire, 
UK).  
 
BrdU incorporation into primary cultured adipocytes 
Primary cultured subcutaneous and mesenteric adipocytes were harvested 
as described previously1. Cells were cultured in Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 0.1 
mg/mL streptomycin, and seeded in a 6-well plate or chamber slide. When 
the cells reached 70% confluence, the medium was changed to 
differentiation medium (DS Pharma Biomedical). Two days later, the 
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medium was exchanged for DMEM, and differentiated adipocytes were 
maintained for 5 d. To assess the proliferation of primary cultured 
adipocytes, the primary adipocytes were incubated with or without 0-100 
μM Pio for 24 h. Ten micromolar BrdU was added for 4 h prior to the end 
of incubation. BrdU-labeled nuclei and adiponectin-positive cytosols were 
visualized by immunostaining using BrdU In-Situ Detection Kit (Becton 
Dickinson), anti-adiponectin antibody and Vectastain ABC kit (Vector 
Laboratories). The proportion of BrdU-labelled cells in a total of 5000 
adiponectin-positive cells was calculated.  
 
Primer sequences 
Quantitative real-time RT-PCR was performed for the validation of 
microarray results using the Thermal Cycler Dice Real Time System 
(TAKARA). Total RNA was isolated and purified as mentioned above. 
Reverse transcription was performed using a PrimeScript Reverse 
Transcriptase (TAKARA, Japan) according to the manufacturer’s 
instructions. Optimal conditions for all investigated genes were established 
using SYBR Premix Ex Taq Kit (TAKARA) according to the 
manufacturer’s instructions. Twenty μl of the reaction solution consisted of 
2 μl of the template, 10 μl of SYBR Premix Ex Taq, 0.4 μl of 10 μM of 
each primer and 0.4 μl of ROX Reference Dye. PCR amplification was 
performed as follows: predenature for 1 cycle at 95℃ for 30s, and 40 
cycles at 95℃for 5s, 60-62℃ for 30s.  Oligonucleotide primers were 
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designed, based on sequences from the GenBank database. 
PPARγ: 5′-CCCTTTGGTGACTTTATGGA-3′ (f) and 
5′-CTGCCTGAGGTCTGTCATCT-3′ (r);  
aP2: 5′-AAAGACAGCTCCTCCTCGAAGGTT-3′ (f) and 
5′-TGACCAAATCCCCATTTACGC-3′ (r);  
LPL: 5′-AGGATGCAACATTGGAGAAG-3′ (f) and 
5′-TCTCTTGGCTCTGACCTTGT-3′ (r);  
FAS: 5′-AGATCCTGGAACGAGAACACGAT-3′ (f) and 
5′-GAGACGTGTCACTCCTGGACTTG-3′ (r);  
adiponectin: 5′-AAGGACAAGGCCGTTCTCT-3′ (f) and 
5′-TATGGGTAGTTGCAGTCAGTTGG-3′ (r);  
IL-6: 5′-GACTTCCATCCAGTTGCCTTCT-3′ (f) and 
5′-TTTTCTCTTTCCACGATTTCC-3′ (r);  
Socs-1: 5′-GACACTCACTTCCGCACCTT-3′ (f) and 
5′-GCAGTTCCGTTGGCGACT-3′ (r);  
MCP-1: 5′-TCACCTGCTGCTACTCATTCAC-3′ (f) and 
5′-CCATTCCTTCTTGGGGTCAG-3′ (r); 
Glut4: 5′-AGTTGGAGAGAGAGCGTCCA-3′ (r) and 
5′-ACCGAGACCAACGTGAAGAC-3′ (r);  
proliferin (PLF): 5′-GGTCGTTGCTTTATGTCCTTTG-3′ (f) and 
5′-GGCTTGTTCCTTGTTTTCTGG-3′ (r); 
GAPDH: 5′-GGCATTGTGGAAGGGCTCAT-3′ (f) and 
5′-GACACATTGGGGGTAGGAACAC-3′ (r).  
To identify the PLF subtype expressed in mature 3T3-L1 adipocytes, PCR 
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for RT product was preformed using the following primers; plf downstream 
exon I, 5′-TAAGCCTGGGTAGGACTCTGC-3′ (45-65) and upstream exon 
V, 5′-CTCTGCAGAGATGCTCCCTTC-3′ (778-756). PCR amplification 
was performed as follows: predenature for 1 cycle at 95 ℃ for 2m, and 40 
cycles at 95℃for 30s, 66℃ for 1m and 72℃ for 1.5m. 
 
siRNA and antibody treatment 
To examine the effect of elimination of PLF on mature 3T3-L1 adipocyte 
proliferation, PLF knockdown with siRNA was preformed. Fully 
differentiated 3T3-L1 adipocytes were re-seeded in 6-well dishes and 
cultured in DMEM. When the cells reached 80% confluence, commercial 
PLF siRNA or negative control (control) siRNA (Santa Cruz) was 
transfected using specific siRNA reagents (TransIT-TKO, Mirus, Madison, 
WI, USA) according to the manufacturer’s instructions. The next day, the 
transfected cells were trypsinized again and seeded in a 6 well plate and 
chamber slide at a density of 3 × 103/cm2. When the cells had attached to 
the plate, the cell number was counted immediately (0 h), and 24 h later. 
BrdU uptake in transfected 3T3-L1 adipocytes was measured as mentioned 
above. Furthermore, re-seeded 3T3-L1 adipocytes at a density of 3 × 
103/cm2 were incubated with 2 μg/ml goat anti-PLF antibody or goat IgG 
(Santa Cruz) for 24 h, followed by cell count and measurement of BrdU 
uptake. In addition, to evaluate whether IGF-II/cation-independent M6P 
receptor and Gi protein, the effects of treatment with 50 ng/ml IGF II and 
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100 ng/ml PTx for 24 h on cell count and BrdU incorporation were 
assessed.   
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SUPPLEMENTARY FIGURE LEGENDS 
 
Supplementary Fig. 1 Comparison between BrdU staining and TUNEL 
staining in individual cells in adipose tissues  
(a, b) To examine the possibility that the BrdU staining in mature 
adipocytes could be attributed to apoptosis, BrdU and TUNEL staining 
were performed on contiguous sections of mesenteric adipose tissue 
isolated from male Wistar rats housed with food containing 0.025% Pio for 
2 wk. The BrdU-labeled cells (a) were not simultaneously stained with 
TUNEL system (b). The solid line arrows represent the BrdU-positive, 
TUNEL-negative cells. The broken line arrows indicate TUNEL-positive 
cells.  
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Supplementary Fig. 2 Immunohistochemical staining of Pref-1 in 
adipose tissue 
(a, b) Subcutaneous adipose tissues isolated from rats housed with food 
containing no Pio (a) or 0.024% Pio (b) for 2 wk were 
immunohistochemically stained for Pref-1 (red) to determine whether 
preadipocyte growth is influenced by Pio administration.  
 
Supplementary Fig. 3 Expression of Pref-1 and adiponectin in 3T3-L1 
preadipocytes and adipocytes 
To rule out the possibility that undifferentiated preadipocytes influenced 
the results for cell number, cell cycle and BrdU incorporation in 3T3-L1 
adipocytes, we assessed the expression of Pref-1 and adiponectin in 3T3-L1 
adipocytes. Immunostaining for Pref-1 in 3T3-L1 preadipocytes (left), 
re-seeded fully differentiated 3T3-L1 adipocytes (middle), and for 
adiponectin in re-seeded fully differentiated 3T3-L1 adipocytes (right) is 
shown. 
 
Supplementary Fig. 4 Expression of PLF during differentiation in 
3T3-L1 adipocytes 
Expression of PLF mRNA (black bars) and PPARγ mRNA (white bars) 
increased during the differentiation of 3T3-L1 adipocytes. The values are 
mRNA copy numbers adjusted for GAPDH mRNA levels. Differentiation 
was initiated on Day 0. Data are presented as mean ± s.e.m of 3 
independent experiments. 
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Supplementary Fig. 5 Sequence comparisons of the PCR product 
(cDNA) with other PLFs   
Total RNA was isolated from 3T3-L1 adipocytes and then RT and PCR of 
PLF were carried out as mentioned in SUPPLEMENTARY METHODS. 
The sequencing of the PCR product was performed by Dragon 
GenomicsCtr, Takarabio Inc. (Mie, Japan) using Applied Biosystems 
3730xl DNA Analyzer (Applied Biosystems). 
 
Supplementary Fig. 6 Effects of PLF knockdown and treatment with 
an anti-PLF antibody on gene expression in 3T3-L1 adipocytes 
(a–e) Effects of siRNA-mediated PLF gene silencing and anti-PLF 
antibody on gene expression, including PLF (a), PPARγ (b,) LPL (c), 
adiponectin (d), and MCP-1 (e), in 3T3-L1 adipocytes. n = 5, *, P < 0.05 vs 
control, **, P < 0.01 vs control, #, P < 0.05 vs Goat IgG. 
  
Supplementary Fig. 7 Expression of PLF in various organs in rat 
PLF protein levels were assayed by Western blot. The images presented are 
representative of 4 independent experiments. BAT, brown adipose tissue; 
WAT, white adipose tissue. 






